Creative Medical Shares Soar On Positive Data from StemSpine Pilot Study

by Vandana Singh, Benzinga Editor

March 23, 2022 10:13 AM | 1 min read |

Creative Medical Technology Holdings CELZ has announced positive two-year follow-up data from its StemSpine pilot study.
The data showed significant efficacy of the StemSpine procedure for treating chronic lower back pain without any serious adverse effects reported.
StemSpine is a patented procedure that utilizes a patient's bone marrow aspirate to treat chronic lower back pain.
There were no safety-related concerns for up to two years, and the StemSpine procedure resulted in an efficacy rate of 87% in the treated patients.
The Company plans to submit a manuscript for publication in a peer-reviewed journal and present the data at future orthopedic/sports medicine conferences.
Price Action: CELZ shares are up 80.30% at $3.07 on the last check Wednesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.